July 10, 2012



As thousands gear up to attend the AIDS 2012 conference in Washington, DC later this month, CONRAD is working closely with our collaborators on joint satellite sessions that will focus on the road ahead for microbicides and regulatory issues related to multipurpose prevention products, as well as several presentations. Following is a list of CONRAD activities. If you are attending the conference, please feel free to join us. Otherwise, contact alarkin@conrad.org for more information. 

Microbicides: The Road Ahead  - Tuesday 24 July 2012 | 18:30-20:30 | Mini Room 2

Despite important advances in HIV prevention and treatment, 2.7 million individuals worldwide are infected with HIV each year, underscoring the urgent need for new, effective, user-controlled prevention methods like microbicides – products that can be applied to the vagina or rectum as a gel, ring, film or tablet to prevent HIV. Microbicide products can provide multiple benefits by also preventing sexually transmitted infections (STIs) and unintended pregnancies. More product choices will make microbicides more available to women and men.

In this session, experts from the leading microbicide development agencies will provide an update on promising new candidates – from deep in the pipeline to ideas closer to market. Because products only work if individuals are motivated to use them and communities will adopt them, advocates, scientists and practitioners will speak to what we know – and what we still need to learn – about the potential for microbicides to make an impact on the epidemic.


  • Cate Hankins, Amsterdam Institute for Global Health and Development 


  • Naomi Rutenberg, Population Council
  • Henry Gabelnick, CONRAD
  • Jeanne Marazzo, MTN
  • Anita Garg, IPM
  • Jim Pickett, IRMA
  • Manju Chatani, AVAC
  • Peter Cherutich, Kenya National AIDS Control Program
  • Linda-Gail Bekker, Desmond Tutu HIV Center

New Products, New Paradigms: Combination Products for Women - Thursday 26 July 2012 | 18:30-20:30 | Mini Room 1

Unprotected sex puts women worldwide at simultaneous risk of HIV, other STIs, particularly herpes simplex virus (HSV) and human papillomavirus (HPV), and unintended pregnancy, all of which impose heavy burdens on morbidity and mortality. Multipurpose prevention technologies (MPTs) which integrate prevention of HIV/other STIs and pregnancy would address these combined risks, enhancing public health impact. A dynamic, conversation-style session is envisioned, which will consider the need, the challenges, and the opportunities for multi-indication products. The session will include audience participation and voting.

  ·         The Case for MPTs:  Dr. Helen Rees, WRHI

 ·         Audience participation:  A selection of product profiles will be reviewed and the audience asked to vote for their ideal product. Polling will be done in real time and results shared with participants.

·         From “Ideal to Real”: What’s in the Product Pipeline?:  Dr. Judy Manning, USAID - Description of first-generation MPTs currently in development.

·         Distilling and Clarifying Regulatory Pathways:  Dr. Charu Mullick, U.S. FDA  - Review of the potential regulatory pathways for dual-indication products.


Andrea Thurman, M.D. Associate Professor of Obstetrics and Gynecology, Eastern Virginia Medical School, will present: Impact of depot medroxyprogesterone (DMPA) on human vaginal leukocytes and HIV-1.

Session Title:  Transmission and Early Infection
Session Date:  Monday, 23 July 2012
Session Time:  17:00 - 17:15

Meredith Clark, Ph.D, Manager, Drug Delivery, is presenting a mini oral poster entitled: Development of a new intravaginal ring technology for the extended delivery of the microbicide tenofovir with and without the contraceptive levonorgestrel.

Session Title:  Sheep Rings and Other Things: New Directions in ARV for Prevention                                                                                                                                                                                                                                                                         Session Date:  Wednesday, 25 Jul 2012                                                                                                                                                                                                                                                                                                                                         Session Time:  13:00-14:00                 

Also during the conference - as the sponsor of the FACTS 001 trial, CONRAD leadership will meet with FACTS 001 leadership and donors to discuss trial progress.  The FACTS 001 study will establish the efficacy of tenofovir gel for the prevention of HIV and HSV-2 infection and the safety of the product in comparison to a matched placebo gel in women.